Li Jieyao, Wang Dan, Zhang Zhen, Sun Kai, Lei Qingyang, Zhao Xuan, Huang Jianmin, Wang Liping, Zhang Yi
Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
J Immunol. 2025 Jun 1;214(6):1272-1280. doi: 10.1093/jimmun/vkaf037.
Cytokine-induced killer (CIK) cells, as an adoptive immunotherapy, are effective at treating colorectal cancer (CRC). However, whether an individual can benefit from CIK cell therapy remains unclear. In this study, we analyzed the long-term effects of CIK cell therapy and specifically the relationship between tumor-associated antigen expression and the survival benefit of CIK cell therapy in patients with CRC. We conducted a retrospective clinical study of 98 patients with CRC who were pathologically diagnosed between 2010 and 2014. Of the patients in the study, 48 received surgery and/or chemotherapy (control group), and 50 received CIK cell infusion with chemotherapy or surgery (CIK group). CIK cells exhibited significant antitumor activity, expressing high levels of CD107 and increasing the apoptosis of CRC cells in vitro. Survival analysis showed that adjuvant CIK cell immunotherapy improved overall survival (OS) and progression-free survival (PFS) of patients with CRC. Moreover, OS and PFS improved significantly, irrespective of the stage of the disease. Furthermore, CIK cell adjuvant therapy significantly increased OS and PFS in patients with carcinoembryonic antigen (CEA) levels lower than 5 ng/ml before surgery, but not in patients with CEA levels above 5 ng/ml. Univariate and multivariate analyses showed that CEA expression is an independent prognostic factor for OS and PFS in the CIK cell treatment group. Adjuvant CIK cell therapy is an effective strategy for prolonging OS and PFS in patients with CRC, especially in those with serum CEA levels below 5 ng/ml.
细胞因子诱导的杀伤（CIK）细胞作为一种过继性免疫疗法，在治疗结直肠癌（CRC）方面具有疗效。然而，个体是否能从CIK细胞治疗中获益仍不明确。在本研究中，我们分析了CIK细胞治疗的长期效果，特别是肿瘤相关抗原表达与CRC患者CIK细胞治疗生存获益之间的关系。我们对98例在2010年至2014年间经病理诊断的CRC患者进行了一项回顾性临床研究。研究中的患者，48例接受了手术和/或化疗（对照组），50例接受了CIK细胞输注联合化疗或手术（CIK组）。CIK细胞表现出显著的抗肿瘤活性，在体外表达高水平的CD107并增加CRC细胞的凋亡。生存分析表明，辅助性CIK细胞免疫治疗改善了CRC患者的总生存期（OS）和无进展生存期（PFS）。此外，无论疾病分期如何，OS和PFS均显著改善。此外，CIK细胞辅助治疗显著提高了术前癌胚抗原（CEA）水平低于5 ng/ml患者的OS和PFS，但对CEA水平高于5 ng/ml的患者则无此效果。单因素和多因素分析表明，CEA表达是CIK细胞治疗组OS和PFS的独立预后因素。辅助性CIK细胞治疗是延长CRC患者OS和PFS的有效策略，尤其是对血清CEA水平低于5 ng/ml的患者。
